Diagnostics & biomarkers

ctDNA Is Becoming the New Argument Over Chemotherapy

Microglia Are Not a Shortcut to Alzheimer’s Certainty

Migraine Still Refuses a Simple Blood Test

Tissue-Agnostic Medicine Has a New Proof Point

Lung Cancer May Be Entering the Chemo-Replacement Fight

A Blood Test Can See Risk. Policy Cannot Yet Hold It.

Britain Has A £1 Billion Pandemic Plan.

Metabolic syndrome may leave a signature in mitochondrial DNA. The biomarker race should not outrun the evidence

Breast Cancer Gets a New PI3K Pathway Option.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
